Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cosmos Health Inc - SIC # 5122 - DRUGS, DRUG PROPRIETARIES, AND DRUGGISTS SUNDRIES
Ticker
Exchange
SIC #
Website
Latest Ticker
COSM
Nasdaq
5122
https://www.cosmosholdingsinc.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cosmos Health Inc
Cosmos Health Commences Development of Cloudscreen 2.0, the New Iteration of its Next Generation AI Drug Repurposing Platform
- Mar 21st, 2024 1:45 pm
Cosmos Health To Receive Regulatory Approval for C-Scrub Disinfectant in the UK, Obtains Initial Purchase Order; Explores Opportunities Outside EU, Eyeing Global $36Bn+ Market
- Mar 19th, 2024 2:10 pm
Cosmos Health Receives Regulatory Approval to Sell Sky Premium Life Products in $1.9Bn UAE Nutritional Supplements Market; Secures Initial Purchase Orders
- Mar 18th, 2024 1:25 pm
Cosmos Health Successfully Completes Acquisition of Pharmatrade’s Assets; Expects to Increase FY 2024 Annual Revenue by over $5 Million
- Feb 29th, 2024 2:25 pm
As Trading Frenzies Grip Penny Stocks, Criticism of Nasdaq Grows
- Feb 23rd, 2024 5:00 am
Taglich Brothers Publishes First Coverage Report on Cosmos Health with a Price Target of $4, a Nearly Five-Fold Increase from Current Share Price
- Feb 21st, 2024 4:50 pm
Taglich Brothers Initiates Coverage of Cosmos Health Inc.
- Feb 21st, 2024 2:30 pm
Cosmos Health CEO, Greg Siokas, Purchases Shares in the Open Market, Showcasing His Confidence in the Company
- Feb 20th, 2024 2:25 pm
Cosmos Health Completes Acquisition of Cloudscreen, a Cutting-Edge AI Platform; Enters Lucrative $25Bn+ Global Drug Repurposing Market
- Jan 23rd, 2024 6:05 pm
Cosmos Health Bolsters Presence in $400Bn+ Global Generic Drugs Market with $3.5M Acquisition of 10-Drug Portfolio
- Jan 18th, 2024 2:25 pm
Cosmos Health Set for Substantial Growth From Acquisitions Completed in 2023
- Dec 27th, 2023 2:27 pm
Cosmos Health Enters into Definitive Agreement to Acquire Type-2 Diabetes Treatment DIABIT-IS X
- Dec 20th, 2023 2:15 pm
Cosmos Health Announces Open Market Stock Purchases by the CEO
- Dec 18th, 2023 2:15 pm
Cosmos Health to Participate at Capital Link’s 'Invest in Greece' Forum in New York
- Dec 8th, 2023 5:45 pm
Cosmos Health Enters into Agreement to Acquire Rights for WIPO-Filed Patent on Drug Targeting CNS Cancers
- Dec 7th, 2023 2:35 pm
Cosmos Health Announces Patent Filing for its Obesity and Weight Management Product
- Dec 1st, 2023 3:25 pm
Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share
- Nov 21st, 2023 2:00 pm
Cosmos Health to Acquire Cloudscreen, a Cutting-Edge AI-Powered Drug Repurposing Platform; Anticipated to Establish Cosmos as a Leader in the $25Bn Global Market and Deliver Unparalleled Returns for Shareholders
- Oct 11th, 2023 1:35 pm
COSMOS HEALTH CEO Issues Letter to Shareholders
- Oct 5th, 2023 12:30 pm
Cosmos Health Actively Exploring Spinoff of R&D Division into a Publicly Listed Standalone Biotech Company
- Sep 27th, 2023 2:30 pm
Scroll